NasdaqGS - Nasdaq Real Time Price USD

Sana Biotechnology, Inc. (SANA)

8.73

+0.18

(+2.11%)

At close: May 17 at 4:00 PM EDT

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Simply Wall St. 8 days ago

SANA
+2.11%
Sana Biotechnology Inc (SANA) Reports First Quarter 2024 Financial Results

Aligns with Analyst Projections Amidst Strategic Clinical Advancements

GuruFocus.com 9 days ago

SANA
+2.11%
Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates

Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Ongoing ARDENT trial for SC291 continues in B-cell malignancies; expect to report additional data in 2024 Enrolling patients in the ongoing GLEAM trial for SC291 in B-cell mediated autoimmune diseases; expect to report initial clinical data in 2024 Enrolling patients in the ongoing VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expe

GlobeNewswire 11 days ago

SANA
+2.11%
Sana Biotechnology to Present at May and June 2024 Investor Conferences

SEATTLE, May 06, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in May and June. The presentations will feature a business overview and update. Sana will present at the Citizens JMP Securities Life Sciences Conference at 11:30 a.m. ET on Monday, May 13, 2024.Sana will present at the BofA Securities 2024 Healthcar

GlobeNewswire 13 days ago

SANA
+2.11%
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration

Notable companies to have witnessed solid earnings acceleration as of now are Sana Biotechnology (SANA), LifeMD (LFMD), Evolus (EOLS) and Expro Group Holdings (XPRO).

Zacks 16 days ago

SANA
+2.11%
Director Patrick Yang Sells 25,000 Shares of Sana Biotechnology Inc (SANA)

Director Patrick Yang has sold 25,000 shares of Sana Biotechnology Inc (NASDAQ:SANA), according to a recent SEC Filing.

GuruFocus.com 2 months ago

SANA
+2.11%
Baillie Gifford Bolsters Stake in Sana Biotechnology Inc

Baillie Gifford (Trades, Portfolio), the renowned investment management firm, has recently expanded its investment portfolio by adding a significant number of shares in Sana Biotechnology Inc (NASDAQ:SANA). This move underscores the firm's confidence in the biotechnology company's growth potential. On February 1, 2024, Baillie Gifford (Trades, Portfolio) acquired an additional 210,603 shares of Sana Biotechnology, reflecting a 2.07% change in their holdings and bringing the total shares owned to 10,360,620.

GuruFocus.com 2 months ago

SANA
+2.11%
^YH103
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in relapsed/refractory NHL and CLL suggest ability to dose safely, demonstrate the desired immune evasion profile, and early clinical efficacy using hypoimmune technology Announced SC291 IND clearance for B-cell mediated autoimmune diseases with goal to report initial clinical data in 2024 Announced SC262 IND

GlobeNewswire 2 months ago

SANA
+2.11%
14 Stocks With Heavy Insider Buying In 2024

In this article, we will take a detailed look at 14 Stocks With Heavy Insider Buying In 2024. For a quick overview of such stocks, read our article 5 Stocks With Heavy Insider Buying In 2024. Markets await latest inflation numbers and the debate regarding soft vs hard landing is expected to persist in the Wall Street for months […]

Insider Monkey 2 months ago

SANA
+2.11%
TNYA

VOXX
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference

SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the Cowen 44th Annual Health Care Conference at 2:50 p.m. ET on Wednesday, March 6, 2024. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of

GlobeNewswire 2 months ago

SANA
+2.11%
Institutional investors are Sana Biotechnology, Inc.'s (NASDAQ:SANA) biggest bettors and were rewarded after last week's US$521m market cap gain

Key Insights Significantly high institutional ownership implies Sana Biotechnology's stock price is sensitive to their...

Simply Wall St. 2 months ago

SANA
+2.11%
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP

Transplant of HIP-modified pancreatic islet cells provided lasting glucose control in a fully immunocompetent non-human primate (NHP), enabling the achievement of exogenous insulin independence without immunosuppression for six month study duration Administration of anti-CD47 antibody after six months demonstrated the principle of graft ablation and a potential safety strategy SEATTLE, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the po

GlobeNewswire 3 months ago

SANA
+2.11%
Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SEATTLE, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has closed its underwritten upsized public offering of 21,772,728 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 4,500,000 additional shares of its common stock, at a price to the public of $5.50 per share and, in lieu of common stock to certain investors,

GlobeNewswire 3 months ago

SANA
+2.11%
Sana Biotechnology Announces Pricing of Upsized Public Offering

SEATTLE, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has priced its underwritten upsized public offering of 17,272,728 shares of its common stock at a price to the public of $5.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 12,727,272 shares of common stock at a price to the public of $5.4999 per pre-funded warra

GlobeNewswire 3 months ago

SANA
+2.11%
Sana Biotechnology Announces Proposed Public Offering of Common Stock

SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock. In addition, Sana intends to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock. All of the shares to be sold in this offering will be sold by Sana. T

GlobeNewswire 3 months ago

SANA
+2.11%
Are You Looking for a Top Momentum Pick? Why Sana Biotechnology (SANA) is a Great Choice

Does Sana Biotechnology (SANA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks 3 months ago

SANA
+2.11%
Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why

Sana Bio (SANA) rallies 105% after the company reports encouraging pipeline progress with its candidates, SC291 and SC262, for oncology and autoimmune indications.

Zacks 3 months ago

SANA
+2.11%
ADMA
$Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies$
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies

Expect to disclose initial SC262 clinical data in 2024SEATTLE, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to initiate a study of SC262 in patients with relapsed or refractory B-cell malignancies, initially in patients who have received prior CD19-directed C

GlobeNewswire 4 months ago

SANA
+2.11%
Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT on Tuesday, January 9, 2024. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations pag

GlobeNewswire 4 months ago

SANA
+2.11%
EVP Christian Hordo Sells 75,000 Shares of Sana Biotechnology Inc (SANA)

In a notable insider transaction, EVP and Chief Business Officer Christian Hordo sold 75,000 shares of Sana Biotechnology Inc (NASDAQ:SANA) on December 15, 2023.

GuruFocus.com 4 months ago

SANA
+2.11%

Performance Overview

Return	SANA	S&P 500
YTD	+113.97%	+11.18%
1-Year	+20.58%	+29.04%
3-Year	-56.35%	+27.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sana Biotechnology, Inc. (SANA)

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Invest In Growth?

Sana Biotechnology Inc (SANA) Reports First Quarter 2024 Financial Results

Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates

Sana Biotechnology to Present at May and June 2024 Investor Conferences

4 Stocks to Keep a Tab on for Amazing Earnings Acceleration

Director Patrick Yang Sells 25,000 Shares of Sana Biotechnology Inc (SANA)

Baillie Gifford Bolsters Stake in Sana Biotechnology Inc

Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

14 Stocks With Heavy Insider Buying In 2024

Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference

Institutional investors are Sana Biotechnology, Inc.'s (NASDAQ:SANA) biggest bettors and were rewarded after last week's US$521m market cap gain

Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP

Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Sana Biotechnology Announces Pricing of Upsized Public Offering

Sana Biotechnology Announces Proposed Public Offering of Common Stock

Are You Looking for a Top Momentum Pick? Why Sana Biotechnology (SANA) is a Great Choice

Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies

Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

EVP Christian Hordo Sells 75,000 Shares of Sana Biotechnology Inc (SANA)

Performance Overview